

9 November 2017

Receipt of R&D Tax Incentive payment

Antisense Therapeutics Limited (“ANP” or “the Company”) would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive refund payment of \$399,374 in relation to expenditure incurred on eligible R&D activities for the 30 June 2017 financial year.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. The products in ANP’s development pipeline are in-licensed from Ionis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). ATL1103 drug designed to block GHR production successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Contact Information:

Website: www.antisense.com.au

Managing Director: Mark Diamond +61 (3) 9827 8999